TrialAnnals of hematology2024

Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.

Gabriel Scheubeck et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.